Scorpius Holdings Inc (SCPX) AI Stock Analysis

Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing, as well as release and stability testing activities. It also provides various process development services, including upstream and downstream development and optimization, analytical method development solutions, and cell line development, testing, and characterization services. Scorpius Holdings serves clients across the biotechnology and biopharmaceutical industries. Formerly known as NightHawk Biosciences, Inc., it changed its name to Scorpius Holdings, Inc. in February 2024 and is based in San Antonio, Texas.

Between FY2020 and FY2024, revenue moved from $2.9M to $6.2M, reflecting a 5-year revenue CAGR of 15.4% from FY2019 to FY2024. However, FY2024 revenue fell 10.7% from $7.0M in FY2023, while gross margin recovered to 48.8% compared to -31.7% in FY2023. Operating margin was -538.2% in FY2024, with net income of -$32.8M. For the trailing twelve months ended December 31, 2025, revenue contracted to $1.7M, with quarterly revenue growth falling 75.1% year-over-year. Operating margin deteriorated to -2056.8% over the trailing twelve months, while diluted EPS stood at -$4.18.

As of December 31, 2025, Scorpius Holdings had $600,786 in cash and short-term investments alongside total debt of $18.1M, resulting in net debt of $17.5M. Total assets stood at $20.8M, and the current ratio was 0.10. The company reported negative equity with shareholders' equity of -$1.33T. In FY2024, operating cash flow was -$26.0M, free cash flow was -$26.9M, and capital expenditures totaled $875,155. Over five years, the share count increased by 1091739.3%.

Scorpius Holdings traded at $0.00 as of October 16, 2026, with a market capitalization of $6,114 and an enterprise value of $17.6M. The stock trades at a price-to-sales multiple of 0.0x and an EV-to-revenue multiple of 10.2x, compared to a median price-to-sales of 4.1x for US-listed Healthcare peers. Its price-to-book ratio is 0.1x. Over the past year, the broader market as measured by the S&P 500 (SPY) returned 16.8%, while its 5-year return reached 83.0%. The stock has a beta of -5.33.

Scorpius Holdings has 1 Strong Buy rating, 0 Buy ratings, 0 Hold ratings, 0 Sell ratings, and 0 Strong Sell ratings. The mean price target is $5.00, compared to the last close of $0.00, representing a difference of 4999900.0%. Over the last four quarters, the company recorded 2 EPS beats.

This page is an AI-written research summary of Scorpius Holdings Inc (SCPX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SCPX income statement, SCPX balance sheet, SCPX key metrics, SCPX analyst forecast, SCPX chart. See the SCPX stock overview for the latest quote and news.